We are live on ! Find out more
BG

Bellevue Group Portfolio holdings

AUM $4.2B
1-Year Est. Return 54.85%
This Fund
S&P 500
This Quarter Est. Return
-7.4%
1 Year Est. Return
+54.85%
3 Year Est. Return
+140.3%
5 Year Est. Return
+171.01%
10 Year Est. Return
+915.55%
AUM
$5.38B
AUM Growth
-$480M
Cap. Flow
+$130M
Cap. Flow %
2.42%
Top 10 Hldgs %
41.73%
Holding
224
New
23
Increased
133
Reduced
36
Closed
13

Top Buys

Rank Stock Value
1
IONS icon
Ionis Pharmaceuticals
IONS
+$23.8M
2
GKOS icon
Glaukos
GKOS
+$20.8M
3
ARVN icon
Arvinas
ARVN
+$19.8M
4
AGIO icon
Agios Pharmaceuticals
AGIO
+$18.4M
5
PACB icon
Pacific Biosciences
PACB
+$13.3M

Top Sells

Rank Stock Value
1
CELG
Celgene Corp
CELG
+$72.6M
2
GILD icon
Gilead Sciences
GILD
+$33.8M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$23.2M
4
TDOC icon
Teladoc Health
TDOC
+$19.5M
5
AVDR
Avedro, Inc Common Stock
AVDR
+$15.8M

Sector Composition

Rank Sector Weight
1 Healthcare 94.28%
2 Industrials 0.53%
3 Technology 0.51%
4 Financials 0.07%
5 Consumer Discretionary 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ALGN icon
26
Align Technology
ALGN
$12.7B
$61.2M 1.14%
338,483
+31,888
+10% +$6.63M
NKTR icon
27
Nektar Therapeutics
NKTR
$2.31B
$57.8M 1.07%
211,526
+36,014
+21% +$13.2M
BSX icon
28
Boston Scientific
BSX
$65.4B
$57.8M 1.07%
1,419,988
+39,206
+3% +$1.66M
DHR icon
29
Danaher
DHR
$144B
$53.7M 1%
419,349
+23,762
+6% +$2.98M
UNH icon
30
UnitedHealth
UNH
$387B
$51.9M 0.96%
238,712
+44,318
+23% +$10.7M
BDX icon
31
Becton Dickinson
BDX
$43.6B
$50.8M 0.94%
205,848
+52,414
+34% +$12.9M
AKCA
32
DELISTED
Akcea Therapeutics Inc
AKCA
$47.9M 0.89%
3,109,911
+9,143
+0.3% +$195K
BMY icon
33
Bristol-Myers Squibb
BMY
$124B
$47.5M 0.88%
937,009
+81,400
+10% +$3.83M
ICPT
34
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$46.6M 0.87%
702,176
-9,627
-1% -$646K
VYGR icon
35
Voyager Therapeutics
VYGR
$192M
$46.5M 0.87%
2,704,683
+24,400
+0.9% +$512K
EW icon
36
Edwards Lifesciences
EW
$49.4B
$42.8M 0.8%
583,296
+61,398
+12% +$4.31M
JAZZ icon
37
Jazz Pharmaceuticals
JAZZ
$15.5B
$42.3M 0.79%
330,227
-1,946
-0.6% -$261K
SYK icon
38
Stryker
SYK
$123B
$40.7M 0.76%
188,284
+29,121
+18% +$6.25M
BOLD
39
DELISTED
Audentes Therapeutics, Inc
BOLD
$40.2M 0.75%
1,429,604
+60,000
+4% +$2.05M
CI icon
40
Cigna
CI
$74.5B
$36.3M 0.68%
239,294
+28,540
+14% +$4.64M
GILD icon
41
Gilead Sciences
GILD
$167B
$35M 0.65%
551,600
-517,600
-48% -$33.8M
CRSP icon
42
CRISPR Therapeutics
CRSP
$4.71B
$34.3M 0.64%
837,162
+26,700
+3% +$1.28M
SGMO
43
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$33M 0.61%
3,650,000
– –
WVE icon
44
Wave Life Sciences
WVE
$1.12B
$31.9M 0.59%
1,552,858
+37,856
+2% +$868K
BAX icon
45
Baxter International
BAX
$11.7B
$31.1M 0.58%
355,568
+41,331
+13% +$3.53M
CNC icon
46
Centene
CNC
$32.8B
$30M 0.56%
692,914
+18,389
+3% +$895K
QTTB icon
47
Q32 Bio
QTTB
$346M
$29.2M 0.54%
89,562
+11,666
+15% +$3.97M
HCA icon
48
HCA Healthcare
HCA
$82.3B
$25.5M 0.47%
211,382
+24,637
+13% +$3.18M
DXCM icon
49
DexCom
DXCM
$29.6B
$25.2M 0.47%
675,548
+15,004
+2% +$583K
GKOS icon
50
Glaukos
GKOS
$9.21B
$25.1M 0.47%
402,148
+294,913
+275% +$20.8M
1
2
3 4 5

Similar funds

WSFS
Wilmington Savings Fund Society Wilmington, Delaware $4.2B AUM 18.37% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $4.22B AUM 21.28% 1-Year Est. Return
HIP
HUB Investment Partners Austin, Texas $4.18B AUM 24.76% 1-Year Est. Return
DT
DV Trading Chicago, Illinois $4.22B AUM
ATPW
Ashton Thomas Private Wealth Scottsdale, Arizona $4.23B AUM 20.9% 1-Year Est. Return
BT
Banque Transatlantique Paris, France $4.17B AUM 28.5% 1-Year Est. Return
NCM
Nearwater Capital Markets Dublin 4, Dublin, Ireland $4.24B AUM 66.03% 1-Year Est. Return
MSU
Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

Bellevue Group's Q3 2019 Portfolio in Review

As of Q3 2019, Bellevue Group held 224 positions worth $5.38B, down 8.2% from $5.86B the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Bellevue Group's Q3 2019 filing shows 23 new, 133 increased, 36 reduced and 13 closed positions. Its largest new stake was Arvinas: 806,403 shares worth $17.4M. The largest sale was Celgene Corp, an estimated $72.6M.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, down from 95% a quarter earlier, followed by Industrials and Technology.

  • Bellevue Group's largest Q3 2019 buy was Arvinas: 806,403 shares worth $17.4M.
  • Bellevue Group added most to Ionis Pharmaceuticals in Q3 2019, an estimated $23.8M increase.
  • Bellevue Group's biggest Q3 2019 reduction was Celgene Corp, cutting an estimated $72.6M.
  • Bellevue Group fully exited Avedro, Inc Common Stock in Q3 2019, selling an estimated $15.8M.
  • Bellevue Group's ten largest holdings make up 42% of its $5.38B portfolio in Q3 2019.
  • Bellevue Group opened 23 new positions and closed 13 in Q3 2019.
  • Bellevue Group's portfolio value fell 8.2% quarter-over-quarter to $5.38B.

Based on Bellevue Group's 13F filing for Q3 2019, filed 14 Nov 2019.